id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_joywji2vabejrc3y6yzx2psqku	Sanjay Kalra	Prospective Multicenter Observational Study of Voglibose in Type 2 Diabetes—VICTORY	2020.0	5	.pdf	application/pdf	4133	533	70	the real-world effectiveness of voglibose in terms of efficacy and safety, and the usage pattern as monotherapy or add-on treatment controlled T2DM (glycated hemoglobin [HbA1c] 7.0–10.0% despite diet, exercise and/or antidiabetic agents), treated with voglibose monotherapy postprandial blood glucose (FBG and PPBG) levels and bodyweight, pattern of usage and safety assessments. Most participants (75%) received voglibose as add-on therapy and the most commonly prescribed Conclusions: Voglibose, monotherapy or add-on therapy, significantly reduced HbA1c, FBG and Voglibose, HbA1c, hyperglycemia, diabetes, observational study or add-on treatment in patients with type 2 diabetes mellitus (T2DM) from study to understand usage and effect of voglibose as monotherapy or add reported reduction in mean HbA1c of 1.96% with voglibose (0.2 mg three Mean reduction of 27.1 mg/dL in FBG was observed in our study. safety and tolerability of voglibose reported in several studies.14,17,16,19–21 voglibose in comparison with acarbose in type 2 diabetic patients.	./cache/work_joywji2vabejrc3y6yzx2psqku.pdf	./txt/work_joywji2vabejrc3y6yzx2psqku.txt